T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. - Wikidata - awgldk - TriplyDB

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

http://www.wikidata.org/entity/Q39300005

about

Novel technologies and emerging biomarkers for personalized cancer immunotherapy Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances Immunological effect of local ablation combined with immunotherapy on solid malignancies.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer Adding fuel to the fire: immunogenic intensification.Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis.Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?Perspectives on treatment of metastatic castration-resistant prostate cancer.Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy Monitoring regulatory immune responses in tumor immunotherapy clinical trials.Understanding the biology of antigen cross-presentation for the design of vaccines against cancer.Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Immunotherapy in prostate cancer: challenges and opportunities.Immunogenomics: using genomics to personalize cancer immunotherapy.PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.Immunotherapy for prostate cancer: False promises or true hope?Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning.Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

P2860

Q26770780-18F690A0-CDCA-4657-9A68-55E142E2850C Q26783783-E20ADA79-4B94-4C05-9B43-CCE0F2C965B3 Q26827475-4DCD135B-211D-4B92-BA2B-4BAAE7601A6C Q30354580-C71D5E65-E6BB-4631-8160-2FD5196F93FE Q33621393-21F56903-E4BA-44DF-AB12-1DC52890FF98 Q33657979-458532B9-90ED-46E1-9B78-5769BEFE29AE Q33688931-BC448C48-DAC4-41BC-80B1-8E5362FFBE7F Q34353251-5505396B-3910-4837-9223-9C17D62B4AB6 Q35713307-A8988520-A460-4C23-924F-9F2C2243FF64 Q35886393-69631690-A879-4BF5-A0CF-5E3F532FEF77 Q36020800-FAF0810F-C51D-4D1C-8EBD-AC43CFCC26EE Q36283876-DC914433-7523-48ED-A56E-0AB6AB982B5F Q36804897-2ADE751B-50CF-4E4E-9BCA-5100CF23CD23 Q36871685-5DD236B5-A2C7-4D3A-989C-877623A1BE43 Q37014134-3BFFDE65-3BFB-40AD-B253-1D78A7E96CAE Q37369239-42CBBCD8-4451-4400-B069-F7AC530B684C Q37652790-5454873D-9BF8-48E4-860C-44BD08D938CE Q38105081-95B03949-C624-42FE-97ED-690FBACE6FDC Q38208305-1AADCF09-B3E5-4762-91FC-41190251CEA9 Q38212231-42F3E516-531D-46D8-85BB-72AD2CE92C81 Q38447992-1F140DFE-E05B-4CB9-BCB1-0369D2DB5081 Q38600417-312866FD-48AE-4426-950D-ED44CF566D30 Q38661079-64E5B1B8-3C77-4789-9BAD-C522DFC836B0 Q38772744-37A6C4AE-DB68-4444-A18B-3DC499F439B5 Q38937417-0428DF7D-A9BA-4736-883B-C72F69E59B62 Q38959645-B691DCD3-57B6-43B8-A832-236C203DC093 Q39069273-FDC1D41D-65B0-4E6B-97C8-79033691E216 Q39084400-53C6203D-94A8-4217-9B09-D878DE9D7ADB Q40437042-C8134D85-5A2D-4615-A152-50C59E8AB222 Q40713858-74A059EF-411B-4FA2-8885-62B3777862AA Q41041538-89A2DB04-AB0C-4C54-9517-ECC4E671A4BB Q41557983-E06087AB-3268-40BC-81BA-386A1B5DA239 Q42549680-C90CC237-8386-4169-94FD-BED12F8D29F4 Q42755227-88652DF1-37C6-4CEF-B523-1639D55F1EE7 Q46971015-E00E596C-CBB3-4E14-9634-A608260AB5ED Q47141309-E73A3BA3-CEB8-4134-BF5E-40CECDFE6F6C Q54511300-045B8A7B-DDDA-4BDD-806E-E918CCF06888

P2860

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

http://www.wikidata.org/entity/Q39300005

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.

@en

T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.

@nl

type

label

T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.

@en

T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.

@nl

prefLabel

T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.

@en

T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.

@nl

P1433

Q39300005-4A52681F-C689-4AEE-AB2D-9D6369B94F30

P1476

Q39300005-5C9495E1-B19F-4370-B439-06AB76B2307B

P2093

Q39300005-064DF052-B393-4607-A3FE-688F29E9DC67

Q39300005-0A7F132C-429A-4490-9FD5-CFA37AFFEB5F

Q39300005-51EF5332-C50A-4F08-ACB8-1AEED2CAC65D

Q39300005-71116AF7-F52C-4E34-A114-3349A69A81E6

Q39300005-7ADC35D2-273B-43B2-8CE2-E167A40CEF35

Q39300005-871B2A55-2452-4FC1-BE42-C891DC272EAA

Q39300005-B9BAE906-35C8-44DA-8F29-F25F1A1C60CF

Q39300005-BDC12055-8B70-4F47-A399-6B2C0038DC66

Q39300005-BDFB910F-7AC6-41FA-8F80-BE3E99BE4CC7

Q39300005-CF21ACE4-0085-4A4E-ABC1-3989B318DAA9

P2860

Q39300005-01EF8012-4DAB-414A-9FD9-6A945181801F

Q39300005-039AEA1D-091C-47A1-BDC0-09B447F6A1C2

Q39300005-0DA6502C-E344-43F5-A19B-533CEFC27ED2

Q39300005-2DCF428E-96A9-4EB8-B857-7AB68233D7C6

Q39300005-315651CE-75BD-445E-8597-A506048A91F1

Q39300005-36A5B86E-2DD2-4EA0-A648-21702B786A41

Q39300005-385B9213-864C-48DC-B7C8-A8BA3FC5D41B

Q39300005-39B45DC4-C998-44D0-81AD-2CE9F16E762A

Q39300005-4110D086-C7AD-4E5F-ADD5-BC862DE2174E

Q39300005-44111209-0C3C-4E57-824C-2ED6F5D798FB

P2888

Q39300005-E1D7583E-1464-4BD8-9303-ACB1675421B4

P304

Q39300005-851CFB71-217A-4295-9DEE-EEBCBEFE4E4C

P31

Q39300005-64FC4603-05A8-4FA8-9600-5A43BACF3A82

P356

Q39300005-2B3CE374-BB99-4153-84AD-35B65E412B14

P433

Q39300005-ECC159EE-8630-493A-918C-CC7A008126FE

P478

Q39300005-19E447AF-4340-4CAD-A69E-8067031A2DFF

P577

Q39300005-D4927840-8A5F-4CF0-9D8C-C074C39A3B99

P698

Q39300005-7AF88F27-C7A4-461E-9A9D-DC537C755B5D

P921

Q39300005-2BFC3821-CD56-4324-ADF8-41B1C6D47F0D

P356

S00262-012-1330-5

P1433

Cancer Immunology, Immunotherapy

P1476

T cell profiling reveals high ...... ate GVAX/ipilimumab treatment.

@en

P2093

Alfons J M van den Eertwegh

http://www.w3.org/2001/XMLSchema#string

Anita G M Stam

http://www.w3.org/2001/XMLSchema#string

B Mary E von Blomberg

http://www.w3.org/2001/XMLSchema#string

Helen Gall

http://www.w3.org/2001/XMLSchema#string

Israel Lowy

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Cuillerot

http://www.w3.org/2001/XMLSchema#string

Karin Jooss

http://www.w3.org/2001/XMLSchema#string

Kristen Hege

http://www.w3.org/2001/XMLSchema#string

Martine Reijm

http://www.w3.org/2001/XMLSchema#string

Natalie Sacks

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Cancer statistics, 2010

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

The B7 family revisited

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

P2888

s00262-012-1330-5

P304

245-256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-012-1330-5

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22878899

http://www.w3.org/2001/XMLSchema#string

P921